Mirati Therapeutics Inc., of San Diego, said it priced an underwritten public offering of 2.75 million shares of its common stock at $38.85 each. In addition, and in lieu of common stock, the company is offering to certain investors pre-funded warrants to purchase up to an aggregate of 421,650 shares of common stock at $38.849 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. Read More
As the first step in implementing a national precision health initiative, Genome Canada this week launched a rare disease pilot program. As part of the pilot, a national cohort will be established with the aim of collecting and sequencing 30,000 samples from patients with rare diseases and their families. Read More
Athersys Inc., of Cleveland, said it entered an agreement with Healios KK, of Tokyo, to expand their collaboration into additional therapeutic areas. Under the terms, Healios obtained exclusive licenses for the development and commercialization in Japan of Multistem therapy for the treatment of acute respiratory distress syndrome (ARDS) and for Multistem cells used in combination with induced pluripotent stem cell (iPSC)-derived cells for the treatment of certain organs. Read More
For nearly a decade, the Federal Trade Commission has been in hot pursuit of the now-defunct Lab MD over allegations of data security violations, but a federal appeals court recently vacated an FTC cease-and-desist order imposed on Lab MD, seeming to bring to a close one of the more conspicuous federal prosecutions for data security lapses in recent memory. Read More
HONG KONG – Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said its Chinese partner, Everest Medicines Ltd., has filed an application with Chinese regulators to initiate the phase III trial of its lead product eravacycline in complicated intra-abdominal infections (cIAIs). Read More
Two gene expression signatures in blood samples of pregnant women could accurately assess the gestational age of the fetus, and predict which pregnancies would end in preterm birth, respectively. Read More
Waltham, Mass.-based Deciphera Pharmaceuticals Inc.'s updated results from its phase I trial with DCC-2618, a broad-spectrum KIT and platelet-derived growth factor receptor (PDGFR) alpha inhibitor, in patients with gastrointestinal stromal tumors (GIST) at the American Society of Clinical Oncology (ASCO) meeting cheered investors. Read More
LONDON – Kandy Therapeutics Ltd. is moving to close a £25 million (US$33.5 million) series C round to fund phase IIb development of NT-814, after announcing positive phase Ib/II results for the oral neurokinin (NK) receptor antagonist in the treatment of symptoms of menopause. Read More
Backed with an upsized $85 million series C financing, Sutrovax Inc. is looking to supplant New York-based Pfizer Inc.'s Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) as the go-to vaccine protecting against Streptococcus pneumonia infection in the $6 billion annual market. Read More
BOSTON - Once upon a time the goalpost for drug development was the coveted FDA approval, but a changing landscape of how products are valued has cornered industry professionals into creating new reimbursement and market adoption strategies. Read More
